Evidence map›Paper›PMID 28988769›Full record

ArticleCell2017

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

A Gordon Robertson, Jaegil Kim, Hikmat Al-Ahmadie, Joaquim Bellmunt, Guangwu Guo, Andrew D Cherniack, Toshinori Hinoue, Peter W Laird, Katherine A Hoadley, Rehan Akbani and 33 more

Erratum issued Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04872036 (Investigation of Prognostic Biomarkers in Patients With Urothelial Carcinoma Treated With Platinum Regimens), which is not on this map. Cited by 1,361 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,361citing papers in PubMed, 4 pooled it
204.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04872036 completednot on this map

Investigation of Prognostic Biomarkers in Patients With Urothelial Carcinoma Treated With Platinum Regimens

TypeobservationalSponsorHellenic Cooperative Oncology GroupRan2000 to 2017Enrolled66ConditionsBladder Cancer
3 · Its place in the literature

Who cites it

1,361 citing papers in PubMed, 4 syntheses or guidelines pooled it, 2,447 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma andJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Trial
  7. Trial
  8. Trial
  9. Dna aneuploidy and urothelial carcinoma: A meta-analysis.Current therapeutic research, clinical and experimental · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

1,301 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

43 authors at 16 institutions in 3 countries.

A Gordon RobertsonCanada's Michael Smith Genome Sciences Center, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Jaegil KimCancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Hikmat Al-AhmadieDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Joaquim BellmuntPSMAR-IMIM Lab, Bladder Cancer Center, Department of Medicine, Dana-Farber Cancer Institute and Harvard University, Boston, MA 02215, USA.
Guangwu GuoDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard University, Boston, MA 02115, USA.
Andrew D CherniackCancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Toshinori HinoueCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, MI 49503, USA.
Peter W LairdCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, MI 49503, USA.
Katherine A HoadleyDepartment of Genetics, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Rehan AkbaniDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mauro A A CastroBioinformatics and Systems Biology Laboratory, Federal University of Paraná Polytechnic Center, Curitiba, PR CEP 80.060-000, Brazil.
Ewan A GibbCanada's Michael Smith Genome Sciences Center, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Rupa S KanchiDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Dmitry A GordeninGenome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC 27709, USA.
Sachet A ShuklaDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard University, Boston, MA 02115, USA.
Francisco Sanchez-VegaCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Donna E HanselDepartment of Pathology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Bogdan A CzerniakDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Victor E ReuterDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Xiaoping SuDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Benilton de Sa CarvalhoBiostatistics and Computational Biology Laboratory, Department of Statistics, University of Campinas, São Paulo, 13.083-859, Brazil.
Vinicius S ChagasBioinformatics and Systems Biology Laboratory, Federal University of Paraná Polytechnic Center, Curitiba, PR CEP 80.060-000, Brazil.
Karen L MungallCanada's Michael Smith Genome Sciences Center, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Sara SadeghiCanada's Michael Smith Genome Sciences Center, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Chandra Sekhar PedamalluCancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Yiling LuDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Leszek J KlimczakIntegrative Bioinformatics Support Group, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC 27709, USA.
Jiexin ZhangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Caleb ChooCanada's Michael Smith Genome Sciences Center, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Akinyemi I OjesinaDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Susan BullmanCancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Kristen M LeraasBiospecimen Core Resource, The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.
Tara M LichtenbergBiospecimen Core Resource, The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Nicholaus SchultzCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Gad GetzCancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Matthew MeyersonPathology and Medical Oncology, Dana-Farber Cancer Institute and Harvard University, Boston, MA 02115, USA.
Gordon B MillsDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
David J McConkeyGreenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD 21218, USA.
TCGA Research Network
John N WeinsteinDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA. Electronic address: jweinste@mdanderson.org.
David J KwiatkowskiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: dk@rics.bwh.harvard.edu.
Seth P LernerScott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: slerner@bcm.edu.
The University of Texas MD Anderson Cancer Center · USBC Cancer Agency · CABroad Institute · USHarvard University · USBrigham and Women's Hospital · USMemorial Sloan Kettering Cancer Center · USNationwide Children's Hospital · USNational Institute of Environmental Health Sciences · USUniversidade Federal do Paraná · BRUniversity of Alabama at Birmingham · USUniversity of North Carolina at Chapel Hill · USVan Andel Institute · USBaylor College of Medicine · USUniversidade Estadual de Campinas (UNICAMP) · BRUniversity of California San Diego · USJohns Hopkins University · US

Funding

Large Scale Sequencing and Analysis of GenomesU54HG003067 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GABRIEL, STACEY, LANDER, ERIC S · 2004 to 2015
$568.6M
Large Scale Genome SequencingU54HG003079 · NHGRI · WASHINGTON UNIVERSITY · PI DUTCHER, SUSAN K · 2004 to 2016
$445.7M
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
The Human Genome Sequencing CenterU54HG003273 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A · 2004 to 2015
$341.3M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHPALL, ELIZABETH J · 2003 to 2023
$43.7M
Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4M
Tuberous Sclerosis-Pathway and PathogenesisP01CA120964 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI David J. Kwiatkowski · 2007 to 2026
$35.9M
Gene Expression Patterns in Human Tumors Identified Using Transcript SequencingU24CA143848 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAYES, DAVID N, PEROU, CHARLES M · 2009 to 2016
$20.8M
Genome-wide hypermutation and structural instabilityZIAES103266 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI GORDENIN, DMITRY · 2015 to 2025
$18.0M
Genome Characterization Center (GCC)U24CA143867 · NCI · BROAD INSTITUTE, INC. · PI GABRIEL, STACEY, MEYERSON, MATTHEW L. · 2009 to 2016
$17.0M
CCR NIH HHS HHSN261200800001CNCATS NIH HHS UL1 TR000371NCI NIH HHS HHSN261200800001ENCI NIH HHS HHSN261201000021CNCI NIH HHS HHSN261201000032CNCI NIH HHS K23 CA160664NCI NIH HHS P01 CA120964NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016086NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA091846NCI NIH HHS P50 CA100632NCI NIH HHS R01 CA155010NCI NIH HHS R01 CA178744NCI NIH HHS R50 CA211482NCI NIH HHS R50 CA221675NCI NIH HHS U01 CA168394NCI NIH HHS U01 CA217842NCI NIH HHS U24 CA143799NCI NIH HHS U24 CA143835NCI NIH HHS U24 CA143840NCI NIH HHS U24 CA143843NCI NIH HHS U24 CA143845NCI NIH HHS U24 CA143848NCI NIH HHS U24 CA143858NCI NIH HHS U24 CA143866NCI NIH HHS U24 CA143867NCI NIH HHS U24 CA143882NCI NIH HHS U24 CA143883NCI NIH HHS U24 CA144025NCI NIH HHS U24 CA199461NCI NIH HHS U24 CA209851NCI NIH HHS U24 CA210949NCI NIH HHS U24 CA210950NCI NIH HHS U24 CA210974NCI NIH HHS U24 CA210999NHGRI NIH HHS U54 HG003067NHGRI NIH HHS U54 HG003079NHGRI NIH HHS U54 HG003273
6 · The paper itself

Abstract

We report a comprehensive analysis of 412 muscle-invasive bladder cancers characterized by multiple TCGA analytical platforms. Fifty-eight genes were significantly mutated, and the overall mutational load was associated with APOBEC-signature mutagenesis. Clustering by mutation signature identified a high-mutation subset with 75% 5-year survival. mRNA expression clustering refined prior clustering analyses and identified a poor-survival "neuronal" subtype in which the majority of tumors lacked small cell or neuroendocrine histology. Clustering by mRNA, long non-coding RNA (lncRNA), and miRNA expression converged to identify subsets with differential epithelial-mesenchymal transition status, carcinoma in situ scores, histologic features, and survival. Our analyses identified 5 expression subtypes that may stratify response to different treatments.

Indexed as

AgedCluster AnalysisDNA MethylationHumansMicroRNAsMiddle AgedMuscle, SmoothRNA, Long NoncodingSurvival AnalysisUrinary BladderUrinary Bladder NeoplasmsMicroRNAsRNA, Long NoncodingAPOBEC mutationbasal mRNA subtypeDNA methylationlncRNA transcriptomeluminal mRNA subtypemicroRNAmuscle-invasive bladder cancerneoantigenneuronal subtyperegulon

Identifiers

PMID28988769
PMCPMC5687509
OpenAlexW2763670669

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.